More importantly, this combined use effectively inhibits the growth and Warburg effect of trastuzumab-resistant cancer cells, suggesting a potential benefit of this regimen in reversing trastuzumab resistance in HER2-positive GC. The gene discussed is ERBB2; the disease is cancer.